MedTrace Logo

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

NCT00974272 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2009-09-10

No results posted yet for this study

Summary

The primary goal of this study is to determine the acute effects of exenatide on postprandial hypertriglyceridemia. Secondary goals are to determine whether there are additional improvements in postprandial lipids and lipoproteins and whether (by the reduction of hyperglycemia alone or in combination with declines in hyperlipidemia) exenatide reduces the pro-inflammatory potential of the postprandial period.

Conditions

Interventions

DRUG

Exenatide

Single subcutaneous injection (10 μg)

OTHER

Normal Saline

Single subcutaneous injection

Sponsors & Collaborators

  • Carl T. Hayden VA Medical Center

    lead FED

Principal Investigators

  • Peter D Reaven, MD · Phoenix VA Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00974272 on ClinicalTrials.gov